Patents by Inventor Feyruz Rassool

Feyruz Rassool has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapy regimen and methods to sensitize cancer cells treated with epigenetic therapy to PARP inhibitors in multiple cancers
    Patent number: 10363264
    Abstract: The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are provided for sensitizing a cell to a PARP inhibitor.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: July 30, 2019
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Feyruz Rassool, Stephen Baylin, Carine Robert
  • Therapy regimen and methods to sensitize cancer cells treated with epigenetic therapy to PARP inhibitors in lung cancer
    Patent number: 10105383
    Abstract: The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are provided for sensitizing a cell to a PARP inhibitor.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: October 23, 2018
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Feyruz Rassool, Stephen Baylin, Carine Robert, Khadiza Chowdhury, Nidal Muvarak
  • Therapy regimen and methods to sensitize cancer cells treated with epigenetic therapy to PARP inhibitors in ovarian cancer
    Patent number: 10105382
    Abstract: The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are provided for sensitizing a cell to a PARP inhibitor.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: October 23, 2018
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Feyruz Rassool, Stephen Baylin, Carine Robert, Khadiza Chowdhury, Nidal Muvarak
  • Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers
    Patent number: 9623008
    Abstract: In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject. In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and/or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase III? inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 18, 2017
    Assignees: STC.UNM, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Alan Edward Tomkinson, Feyruz Rassool
  • THERAPY REGIMEN AND METHODS TO SENSITIZE CANCER CELLS TREATED WITH EPIGENETIC THERAPY TO PARP INHIBITORS IN LUNG CANCER
    Publication number: 20160367582
    Abstract: The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are provided for sensitizing a cell to a PARP inhibitor.
    Type: Application
    Filed: September 1, 2016
    Publication date: December 22, 2016
    Applicants: THE JOHNS HOPKINS UNIVERSITY, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Feyruz RASSOOL, Stephen BAYLIN, Carine ROBERT, Khadiza Chowdhury, Nidal Muvarak
  • THERAPY REGIMEN AND METHODS TO SENSITIZE CANCER CELLS TREATED WITH EPIGENETIC THERAPY TO PARP INHIBITORS IN OVARIAN CANCER
    Publication number: 20160367581
    Abstract: The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are provided for sensitizing a cell to a PARP inhibitor.
    Type: Application
    Filed: September 1, 2016
    Publication date: December 22, 2016
    Applicants: THE JOHNS HOPKINS UNIVERSITY, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Feyruz RASSOOL, Stephen BAYLIN, Carine ROBERT, Khadiza Chowdhury, Nidal Muvarak
  • THERAPY REGIMEN AND METHODS TO SENSITIZE CANCER CELLS TREATED WITH EPIGENETIC THERAPY TO PARP INHIBITORS IN MULTIPLE CANCERS
    Publication number: 20160346306
    Abstract: The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are provided for sensitizing a cell to a PARP inhibitor.
    Type: Application
    Filed: January 21, 2015
    Publication date: December 1, 2016
    Applicants: THE JOHNS HOPKINS UNIVERSITY, University of Maryland, Baltimore
    Inventors: Feyruz RASSOOL, Stephen BAYLIN, Carine ROBERT
  • TARGETING ABNORMAL DNA REPAIR IN THERAPY-RESISTANT BREAST AND PANCREATIC CANCERS
    Publication number: 20160051517
    Abstract: In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject. In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and/or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase III? inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.
    Type: Application
    Filed: July 8, 2015
    Publication date: February 25, 2016
    Inventors: Alan Edward Tomkinson, Feyruz Rassool
  • Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers
    Patent number: 9132120
    Abstract: In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject. In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and/or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase III? inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: September 15, 2015
    Assignees: STC.UNM, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Alan Edward Tomkinson, Feyruz Rassool